trending Market Intelligence /marketintelligence/en/news-insights/trending/4maga8qx0b3tbxtitanqia2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us
In This List

Sun BioPharma board member resigns

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Sun BioPharma board member resigns

Sun BioPharma Inc. said that Dalvir Gill has resigned from the company's board, effective Aug. 30.

The company said in a Sept. 6 filing that Gill resigned in order to focus on other responsibilities.

Gill joined the board of the Waconia, Minn.-based biotechnology company as an independent director in March 2016. He has served as the CEO of TransCelerate BioPharma Inc. since January 2013.

Sun BioPharma develops disruptive therapeutics for severe unmet medical needs. The company focuses on diseases of the pancreas, including pancreatitis and pancreatic cancer.